UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 31, 2023

LEIDOS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33072

20-3562868

	(State or other jurisdiction of incorporation or organization)	(Commission File Number) (I.R.S. Employer Identification No.)
	1750 Presidents Street, Reston, Virginia (Address of principal executive office)		20190 (Zip Code)
		(571) 526-6000	
	(Registrants' to	elephone number, including area code)	
	ck the appropriate box below if the Form 8-K filing is intended to isions:	simultaneously satisfy the filing ob	ligation of the registrant under any of the following
	Written communications pursuant to Rule 425 under the Secu	rities Act (17 CFR 230.425)	
	Soliciting material pursuant to Rule 14a-12 under the Exchan	ge Act (17 CFR 240.14a-12)	
	Pre-commencement communications pursuant to Rule 14d-2	(b) under the Exchange Act (17 CF	R 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4	(c) under the Exchange Act (17 CF	R 240.13e-4(c))
eci	urities registered pursuant to Section 12(b) of the Act:		
	Title of each class	Trading symbol(s)	Name of each exchange on which registered
	Common stock, par value \$.0001 per share	LDOS	New York Stock Exchange
	cate by check mark whether the registrant is an emerging growtl ule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 c	. ,	of the Securities Act of 1933 (§230.405 of this chapter
			Emerging growth company \Box
	emerging growth company, indicate by check mark if the regist sed financial accounting standards provided pursuant to Section		nded transition period for complying with any new or

FORM 8-K

Item 2.02. Results of Operations and Financial Condition.

On October 31, 2023, Leidos Holdings, Inc. (the "Company") issued a press release announcing its financial results for the third fiscal quarter ended September 29, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report.

The Company's management will discuss operations and financial results in an earnings conference call beginning at 8:00 a.m. eastern on October 31, 2023. A live audio broadcast of the conference call along with a supplemental presentation will be available to the public through links on the Investor Relations section of the Company's web site (http://investors.leidos.com).

The information contained in Item 2.02 of this report and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(i) Exhibits

Exhibit 99.1 Press Release dated October 31, 2023, issued by Leidos Holdings, Inc.

Exhibit 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL and contained in Exhibit 101.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LEIDOS HOLDINGS, INC.

Date: October 31, 2023 By: /s/ Christopher R. Cage

Christopher R. Cage

Its: Executive Vice President and Chief Financial

Officer

Leidos Holdings, Inc. Reports Third Quarter Fiscal Year 2023 Results

- Revenues of \$3.9 billion, up 9% year-over-year
- Net loss of \$396 million or \$2.91 per diluted share
- Adjusted EBITDA of \$451 million (11.5% margin)
- Non-GAAP Diluted Earnings per Share of \$2.03, up 28% year-over-year
- Cash Flows from Operations of \$795 million; Free Cash Flow of \$745 million
- Net Bookings of \$7.9 billion (book-to-bill ratio of 2.0 for the quarter and 1.2 for trailing twelve months)

RESTON, Va., October 31, 2023 – Leidos Holdings, Inc. (NYSE: LDOS), a FORTUNE 500® science and technology leader, today reported financial results for the third guarter of fiscal year 2023.

Thomas Bell, Leidos Chief Executive Officer, commented, "Our third quarter financial results build on the momentum from last quarter and are the direct result of our entire team being aligned on our direction and intent on delivering against our commitments. With record revenues, non-GAAP earnings, cash flow, bookings, and backlog, our growth outlook is improving, and we are raising our guidance for all 2023 financial metrics. As we sharpen our strategy and better align our organization, our focus on differentiating technology will enable us to unlock our full potential and heighten our value proposition to our customers, our nation, and its allies."

Summary Operating Results

	Three Months Ended							
(in millions, except margin and per share data)	Septemb	er 29, 2023	September 30, 2022					
Revenues	\$	3,921 \$	3,608					
Net (loss) income	\$	(396) \$	164					
Net (loss) income margin		(10.1)%	4.5 %					
Diluted earnings per share (EPS)	\$	(2.91) \$	1.17					
Non-GAAP Measures*:								
Adjusted EBITDA	\$	451 \$	372					
Adjusted EBITDA margin		11.5 %	10.3 %					
Non-GAAP diluted EPS	\$	2.03 \$	1.59					

^{*} Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another measure of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures.

Revenues for the quarter were \$3.92 billion, up 9% compared to the third quarter of 2022. Revenues grew year-over-year due to increased demand across all customer segments, especially for digital modernization and medical examination solutions.

For the third quarter, Leidos had a net loss of \$396 million, or \$2.91 per diluted share, which reflected pre-tax, non-cash impairment and restructuring charges of \$699 million primarily associated with the Security Enterprise Solutions (SES) reporting unit. Net income and diluted EPS were down 341% and 349% year-over-year, respectively.

Adjusted EBITDA was \$451 million for the third quarter, up 21% year-over-year. Adjusted EBITDA margin of 11.5% increased from 10.3% in the third quarter of 2022. Non-GAAP net income was \$283 million for the third quarter, up 28% year-over-year, and non-GAAP diluted EPS for the quarter was \$2.03, up 28% year-over-year. The primary drivers of increased profitability were improved business mix as well as increased volumes, higher incentive awards, and recovery of prior expenditures in the medical examination business.

Cash Flow Summary

In the third quarter, Leidos generated \$795 million of net cash provided by operating activities and used \$52 million in investing activities and \$249 million in financing activities. Net cash provided by operating activities benefited from strong collections and working capital management, driven in part from U.S. Government customers accelerating payments at the end of their fiscal year. Days Sales Outstanding (DSO) for the guarter was 57, a 2-day improvement from the second guarter of 2023.

Investing activities consisted primarily of \$50 million in property, equipment and software payments, which resulted in quarterly free cash flow of \$745 million. Financing activities included repayment of \$200 million of commercial paper and \$50 million returned to shareholders as part of a regular quarterly cash dividend program. As of September 29, 2023, Leidos had \$750 million in cash and cash equivalents and \$4.7 billion of debt.

On October 27, 2023, the Leidos Board of Directors declared a cash dividend of \$0.38 per share, which represents an increase of 6% over the prior quarter's dividend amount. The dividend will be payable on December 29, 2023, to stockholders of record at the close of business on December 15, 2023.

Business Development

Net bookings totaled \$7.9 billion in the quarter, representing a book-to-bill ratio of 2.0. As a result, backlog at the end of the quarter was \$38.0 billion, of which \$9.0 billion was funded. Included in the quarterly bookings were several notable awards:

- Common Hardware Systems 6th Generation (CHS-6). The U.S. Army Program Executive Office awarded Leidos a ten-year, firm-fixed price contract with a maximum value of \$7.9 billion. The single-award, indefinite delivery, indefinite quantity (IDIQ) contract has a base period of performance of four years with two three-year options. Under the CHS-6 contract, Leidos will incorporate artificial intelligence (AI) and predictive analytics to increase visibility into operations and provide a uniquely resilient rapid fulfillment model. Leidos will leverage current commercial technology and industry investments to help enhance mission readiness of complex IT hardware across its entire lifecycle. Leidos will also work to deploy a logistics platform to proactively manage supply chain and cybersecurity risks while minimizing total lifecycle costs. Equipment and services procured under the terms of this contract will be used to support a unified network for Multi-Domain Operations (MDO) and Joint All Domain Command and Control (JADC2).
- Homeland Enterprise Information Technology Secure Services and Support (HEITS). Under a \$918 million, seven-year contract, Leidos will continue to support and enhance Department of Homeland Security (DHS) networks. While supporting crossagency intelligence sharing and secure collaboration for federal and civilian agencies, Leidos will deliver leading-edge capabilities, including quantum resistant cryptography. All operations, robotic process automation and classified cloud service integration.
- Army Missile and Space Cyber Electromagnetic Activities (CEMA). The U.S. Army Program Executive Office (PEO) Missiles and Space (M&S) awarded Leidos a \$125 million, five-year task order to design, develop, integrate, test, and deliver high-fidelity prototype virtualizations of critical computing hardware and software components for PEO M&S weapon systems. This work will enhance the mission effectiveness of the warfighter in a contested CEMA environment and will include weapon system critical computing hardware and software emulations, CEMA detection algorithms, tools, models, interfaces, studies, and analysis products.

Forward Guidance

Leidos is updating its fiscal year 2023 guidance as follows:

	FY23 G	uidance
Measure	Current	Prior
Revenues (billions)	\$15.1 - \$15.3	\$14.9 - \$15.2
Adjusted EBITDA Margin	10.5% - 10.7%	10.1% - 10.5%
Non-GAAP Diluted EPS	\$6.80 - \$7.10	\$6.40 - \$6.80
Cash Flows Provided by Operating Activities (millions)	at or above \$850	at or above \$700

For information regarding adjusted EBITDA margin and non-GAAP diluted EPS, see the related explanations and reconciliations to GAAP measures included elsewhere in this release.

Leidos does not provide a reconciliation of forward-looking adjusted EBITDA margins or non-GAAP diluted EPS to net income due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate projected net income may vary significantly based on actual events, Leidos is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income at this time. The amounts of these deductions may be material and, therefore, could result in projected net income and diluted EPS being materially less than what may be implied by projected adjusted EBITDA margins and non-GAAP diluted EPS.

Conference Call Information

Leidos management will discuss operations and financial results in an earnings conference call beginning at 8:00 A.M. eastern time on October 31, 2023. Analysts and institutional investors may participate by dialing +1 (877) 869-3847 (toll-free U.S.) or +1 (201) 689-8261 (international callers).

A live audio broadcast of the conference call along with a supplemental presentation will be available to the public through links on the Leidos Investor Relations website (http://ir.leidos.com).

After the call concludes, an audio replay can be accessed on the Leidos Investor Relations website or by dialing +1 (877) 660-6853 (toll-free U.S.) or +1 (201) 612-7415 (international callers) and entering conference ID 13741334.

About Leidos

Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil and health markets. Leidos' 47,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately \$14.4 billion for the fiscal year ended December 30, 2022.

For more information, visit <u>www.leidos.com</u>.

Forward-Looking Statements

Certain statements in this release contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "guidance" and similar words or phrases. Forward-looking statements in this release include, among others, estimates of our future growth, strategy and financial and operating performance, including future revenues, adjusted EBITDA margins, diluted EPS (including on a non-GAAP basis) and cash flows provided by operating activities, as well as statements about our business contingency plans, government budgets and the ongoing Continuing Resolution, uncertainties in tax due to new tax legislation or other regulatory developments, strategy, planned investments, sustainability goals and our future dividends, share repurchases, capital expenditures, debt repayments, acquisitions, dispositions and cash flow conversion. These statements reflect our belief and assumptions as to future events that may not prove to be accurate.

Actual performance and results may differ materially from those results anticipated by our guidance and other forward-looking statements made in this release depending on a variety of factors, including, but not limited to: developments in the U.S. government defense and nondefense budgets, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the U.S. government budget process or a government shutdown, or the U.S. government's failure to raise the debt ceiling, which increases the possibility of a default by the U.S. government on its debt obligations, related credit-rating downgrades, or an economic recession; uncertainties in tax due to new tax legislation or other regulatory developments; rising inflationary pressures and fluctuations in interest rates; delays in the U.S. government contract procurement process or the award of contracts and delays or loss of contracts as a result of competitor protests; changes in U.S. government procurement rules, regulations and practices; our compliance with various U.S. government and other government procurement rules and regulations; governmental reviews, audits and investigations of our company: our ability to effectively compete and win contracts with the U.S. government and other customers; our ability to respond rapidly to emerging technology trends, including the use of artificial intelligence; our reliance on information technology spending by hospitals/healthcare organizations; our reliance on infrastructure investments by industrial and natural resources organizations; energy efficiency and alternative energy sourcing investments; investments by U.S. government and commercial organizations in environmental impact and remediation projects; the effects of health epidemics, pandemics and similar outbreaks may have on our business, financial position, results of operations and/or cash flows; our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees; our ability to accurately estimate costs, including cost increases due to inflation, associated with our firm-fixed-price contracts and other contracts; resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues; cybersecurity, data security or other security threats, system failures or other disruptions of our business; our compliance with international, federal, state and local laws and regulations regarding privacy, data security, protection, storage, retention, transfer and disposal, technology protection and personal information; the damage and disruption to our business resulting from natural disasters and the effects of climate change; our ability to effectively acquire businesses and make investments; our ability to maintain relationships with prime contractors, subcontractors and joint venture partners; our ability to manage performance and other risks related to customer contracts: the failure of our inspection or detection systems to detect threats; the adequacy of our insurance programs, customer indemnifications or other liability protections designed to protect us from significant product or other liability claims, including cybersecurity attacks; our ability to manage risks associated with our international business; our ability to comply with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act of 2010 and similar worldwide anti-corruption and anti-bribery laws and regulations; our ability to protect our intellectual property and other proprietary rights by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to prevail in litigation brought by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to declare or increase future dividends based on our earnings, financial condition, capital requirements and other factors, including compliance with applicable law and our agreements; our ability to grow our commercial health and infrastructure businesses, which could be negatively affected by budgetary constraints faced by hospitals and by developers of energy and infrastructure projects; our ability to successfully integrate acquired businesses; and our ability to execute our business plan and long-term management initiatives effectively and to overcome these and other known and unknown risks that we face.

These are only some of the factors that may affect the forward-looking statements contained in this release. For further information concerning risks and uncertainties associated with our business, please refer to the filings we make from time to time with the U.S. Securities and Exchange Commission ("SEC"), including the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" sections of our latest Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, all of which may be viewed or obtained through the Investor Relations section of our website at www.leidos.com.

All information in this release is as of October 31, 2023. Leidos expressly disclaims any duty to update the guidance or any other forward-looking statement provided in this release to reflect subsequent events, actual results or changes in Leidos' expectations. Leidos also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

CONTACTS:

Investor Relations: Stuart Davis 571.526.6124 ir@leidos.com Media Relations: Melissa Lee Dueñas 571.526.6850 Duenasml@leidos.com

LEIDOS HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data)

		Three Mor	nths Ended	Nine Months Ended				
	Sep	tember 29, 2023	September 30, 2022	- ;	September 29, 2023	Se	eptember 30, 2022	
Revenues	\$	3,921	\$ 3,608	\$	11,458	\$	10,699	
Cost of revenues		3,334	3,095		9,809		9,136	
Selling, general and administrative expenses		239	232		709		730	
Acquisition, integration and restructuring costs		5	4		14		12	
Goodwill impairment charges		599	_		599		_	
Asset impairment charges		88	_		88		3	
Equity earnings of non-consolidated subsidiaries		(8)	(4)		(21)		(5)	
Operating (loss) income		(336)	281		260		823	
Non-operating income (expense):								
Interest expense, net		(53)	(50)		(163)		(148)	
Other income (expense), net		1	(10)		(4)		(7)	
(Loss) income before income taxes		(388)	221		93		668	
Income tax expense		(8)	(57)		(115)		(155)	
Net (loss) income		(396)	164		(22)		513	
Less: net income attributable to non-controlling interest		3	2		8		5	
Net (loss) income attributable to Leidos common stockholders	\$	(399)	\$ 162	\$	(30)	\$	508	
	<u> </u>							
Earnings per share:								
Basic	\$	(2.91)	\$ 1.18	\$	(0.22)	\$	3.71	
Diluted		(2.91)	1.17		(0.22)		3.68	
Weighted average number of common shares outstanding:								
Basic		137	137		137		137	
Diluted		137	138		137		138	
Cash dividends declared per share	\$	0.36	\$ 0.36	\$	1.08	\$	1.08	

LEIDOS HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, except share and per share data)

	Sep	otember 29, 2023	De	cember 30, 2022
Assets:				
Cash and cash equivalents	\$	750	\$	516
Receivables, net		2,452		2,350
Inventory, net		295		287
Other current assets		494		490
Total current assets		3,991		3,643
Property, plant and equipment, net		935		847
Intangible assets, net		713		952
Goodwill		6,079		6,696
Operating lease right-of-use assets, net		512		545
Other long-term assets		527		388
Total assets	\$	12,757	\$	13,071
Liabilities:				
Accounts payable and accrued liabilities	\$	2,221	\$	2,254
Accrued payroll and employee benefits		801		701
Short-term debt and current portion of long-term debt		18		992
Total current liabilities		3,040		3,947
Long-term debt, net of current portion		4,667		3,928
Operating lease liabilities		527		570
Deferred tax liabilities		6		40
Other long-term liabilities		314		233
Total liabilities		8,554		8,718
Stockholders' equity:				
Common stock, \$0.0001 par value, 500,000,000 shares authorized, 137,506,136 and 136,926,990				
shares issued and outstanding at September 29, 2023, and December 30, 2022, respectively		_		_
Additional paid-in capital		2,055		2,005
Retained earnings		2,186		2,367
Accumulated other comprehensive loss		(95)		(73)
Total Leidos stockholders' equity		4,146		4,299
Non-controlling interest		57		54
Total stockholders' equity		4,203		4,353
Total liabilities and stockholders' equity	\$	12,757	\$	13,071

LEIDOS HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions)

Cash flows from operations: September 20, 20022 September 30, 20022 Composition 20, 20022 Composition 20, 20022 Composition 20, 20022 September 30, 20022 September		Three Mor	nths Ended	Nine Mon	is Ended	
Net (loss) income \$ (396) \$ 164 \$ (22) \$ 513						
Adjustments to reconcile net (loss) income to net cash provided by operations: Depreciation and amortization 82 81 81 248 249 Stock-based compensation 20 18 57 53 50 192 (221) Goodwill impairment charges 599 —						
operations: Security 82 81 248 249 Stock-based compensation 20 18 57 53 Deferred income taxes (104) (85) (192) (221) Goodwill impairment charges 599 — 599 — Asset impairment charges 88 3 88 3 Other 19 14 25 21 Change in assets and liabilities, net of effects of acquisitions and dispositions: 88 3 88 3 Receivables 14 99 (109) (139) Other current assets and other long-term assets 92 59 141 132 Accounts payable and accrued liabilities and other long-term liabilities 20 196 22 (70) Income taxes receivable/payable 24 64 (101) 109 Net cash provided by operating activities 795 729 861 867 Cash flows from investing activities 795 729 861 867 Cash flows f	Net (loss) income	\$ (396)	\$ 164	\$ (22)	\$ 513	
Sicok-based compensation 20 18 57 53 53 52 53 53 53 54 54 55 54 55 54 55 50						
Deferred income taxes	Depreciation and amortization	82			249	
Asset impairment charges	Stock-based compensation					
Asset impairment charges 88 3 88 3 88 3 3 60 Other 19 14 25 21 21 21 21 21 21 21 21 21 21 21 21 21		(104)	(85)	(192)	(221)	
Change in assets and liabilities, net of effects of acquisitions and dispositions: Receivables		599	_	599	_	
Change in assets and liabilities, net of effects of acquisitions and dispositions: 14 99 (109) (139) Receivables 14 99 (109) (139) Other current assets and other long-term assets 92 59 141 132 Accounts payable and accrued liabilities and other long-term liabilities 20 196 22 (70) Accrued payroll and employee benefits 137 116 105 217 Income taxes receivable/payable 24 64 (101) 109 Net cash provided by operating activities 795 729 861 867 Cash flows from investing activities 867 - - - - - 15 Acquisition of a businesss, net of cash acquired (2) - (6) (2) Divestiture of a business - - - - 15 Payments for property, equipment and software (50) (27) (129) (76) Net proceeds from sale of assets - - - - - - <td>Asset impairment charges</td> <td>88</td> <td>3</td> <td>88</td> <td></td>	Asset impairment charges	88	3	88		
Accounts payable and accrued liabilities and other long-term assets 92 59 141 132		19	14	25	21	
Other current assets and other long-term assets 92 59 141 132 Accounts payable and accrued liabilities and other long-term liabilities 220 196 22 (70) Accrued payroll and employee benefits 137 116 105 217 Income taxes receivable/payable 24 64 (101) 109 Net cash provided by operating activities 795 729 861 867 Cash flows from investing activities: - - - - - - 15 Acquisition of a business, net of cash acquired (2) - (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (6) (2) (7) (129) (76) (7) (129) (76) (70) (70) (72) (129) (76) (70) (70) (70) (70) (70) (70)	dispositions:					
Accounts payable and accrued liabilities and other long-term liabilities 220 196 22 (70) Accrued payroll and employee benefits 137 116 105 217 Income taxes receivable/payable 24 64 (101) 109 Net cash provided by operating activities 795 729 861 867 Cash flows from investing activities: 867 861 867 Acquisition of a business, net of cash acquired (2) — (6) (2) Divestiture of a business, net of cash acquired (50) (27) (129) (76) Net proceeds from sale of assets — — — — — 15 Payments for property, equipment and software (50) (27) (129) (76) Net proceeds from sale of assets — — — — — — 15 Net proceeds from sale of assets — — 1 — — 2 Other State of assets — — 1 — —	Receivables	14	99	(109)	(139)	
Itabilities	Other current assets and other long-term assets	92	59	141	132	
Income taxes receivable/payable 24 64 (101) 109 Net cash provided by operating activities 795 729 861 867 Cash flows from investing activities	Accounts payable and accrued liabilities and other long-term liabilities	220	196	22	(70)	
Net cash provided by operating activities 795 729 861 867 Cash flows from investing activities: — — — (6) (2) Divestiture of a business, net of cash acquired (2) — — — — 15 Payments for property, equipment and software (50) (27) (129) (76) Net proceeds from sale of assets — — — — 6 Other — — — — 6 Other — — — — 6 Other — — 1 — 2 Net cash used in investing activities — — 1 — 2 Cash flows from financing activities — — — 1 4 2 Cash used in investing activities — — — — 1,743 380 Net payments from commercial paper (200) (150) — — — — (7)	Accrued payroll and employee benefits	137	116	105	217	
Cash flows from investing activities: Caquisition of a business, net of cash acquired (2) — (6) (2) Divestiture of a business — — — — 15 Payments for property, equipment and software (50) (27) (129) (76) Net proceeds from sale of assets — — — — 6 Other — 1 — 2 Net cash used in investing activities (52) (26) (135) (55) Cash flows from financing activities: — — 1,743 380 Net payments from fondet issuance — — 1,743 380 Net payments from commercial paper (200) (150) — — Repayments of oborrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — (7) — Payments for debt issuance costs — — (7) — Dividend payments (50) (49) (150) (149) Reparchases of stock and other (1) (4) (44) <t< td=""><td></td><td> 24</td><td>64</td><td>(101)</td><td>109</td></t<>		 24	64	(101)	109	
Acquisition of a business, net of cash acquired (2) — (6) (2) Divestiture of a business — — — — 15 Payments for property, equipment and software (50) (27) (129) (76) Net proceeds from sale of assets — — — — 6 Other — — 1 — 2 Net cash used in investing activities (52) (26) (135) (55) Cash flows from financing activities: — — — 1,743 380 Net payments from debt issuance — — — 1,743 380 Net payments for debt issuance costs — — — 1,743 380 Payments for debt issuance costs — — — 1,743 380 Payments for debt issuance costs — — — 1,743 380 Repayments of oborrowings (50) (49) (150) (149) Repayments for debt issuance (50) <td>Net cash provided by operating activities</td> <td>795</td> <td>729</td> <td>861</td> <td>867</td>	Net cash provided by operating activities	795	729	861	867	
Divestiture of a business	Cash flows from investing activities:					
Payments for property, equipment and software (50) (27) (129) (76) Net proceeds from sale of assets — — — — 6 Other — — 1 — 2 Net cash used in investing activities — — 1,743 380 Cash flows from financing activities: — — — 1,743 380 Net payments from commercial paper (200) (150) — — — Repayments of borrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — — (7) — Repayments of oborrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — — (7) — Repayments of oborrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — — (7) — Dividend payments (50) (49) (150)	Acquisition of a business, net of cash acquired	(2)	_	(6)	(2)	
Net proceeds from sale of assets — — — — 6 Other — 1 — 2 Net cash used in investing activities (52) (26) (135) (55) Cash flows from financing activities: — — 1,743 380 Net payments from debt issuance — — — 1,743 380 Net payments from commercial paper (200) (150) —	Divestiture of a business	_	_	_	15	
Other — 1 — 2 Net cash used in investing activities (52) (26) (135) (55) Cash flows from financing activities: Proceeds from debt issuance — 1,743 380 Net payments from commercial paper (200) (150) — — — Repayments of borrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — — (7) — Dividend payments (50) (49) (150) (149) Repurchases of stock and other (1) (4) (44) (532) Proceeds from issuances of stock 12 13 37 35 Net capital distributions to non-controlling interests (5) (2) (8) (5) Net cash used in financing activities (249) (217) (470) (730) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash 491 505 256 96 Cash, cash equivalents and restricted c	Payments for property, equipment and software	(50)	(27)	(129)	(76)	
Net cash used in investing activities (52) (26) (135) (55) Cash flows from financing activities: Proceeds from debt issuance — — 1,743 380 Net payments from commercial paper (200) (150) — <td r<="" td=""><td>Net proceeds from sale of assets</td><td>_</td><td>_</td><td>_</td><td>6</td></td>	<td>Net proceeds from sale of assets</td> <td>_</td> <td>_</td> <td>_</td> <td>6</td>	Net proceeds from sale of assets	_	_	_	6
Cash flows from financing activities: Proceeds from debt issuance — — 1,743 380 Net payments from commercial paper (200) (150) — — Repayments of borrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — (7) — Dividend payments (50) (49) (150) (149) Repurchases of stock and other (1) (4) (44) (532) Proceeds from issuances of stock 12 13 37 35 Net capital distributions to non-controlling interests (5) (2) (8) (5) Net capital distributions to non-controlling interests (5) (2) (8) (5) Net capital distributions to non-controlling interests (5) (2) (8) (5) Net capital distributions to non-controlling interests (249) (217) (470) (730) Effect of foreign exchange rate changes on cash, cash equivalents (3) 19 — 14 Net increase in cash, cash equivalents and restricted cash 491 505 256 96 </td <td>Other</td> <td></td> <td>1</td> <td>_</td> <td>2</td>	Other		1	_	2	
Proceeds from debt issuance — — 1,743 380 Net payments from commercial paper (200) (150) — — Repayments of borrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — — (7) — Dividend payments (50) (49) (150) (149) Repurchases of stock and other (1) (4) (44) (532) Proceeds from issuances of stock 12 13 37 35 Net capital distributions to non-controlling interests (5) (2) (8) (5) Net cash used in financing activities (249) (217) (470) (730) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (3) 19 — 14 Net increase in cash, cash equivalents and restricted cash 491 505 256 96 Cash, cash equivalents and restricted cash at beginning of period 448 466 683 875 Cash, cash equivalents and restricted cash at end	Net cash used in investing activities	(52)	(26)	(135)	(55)	
Net payments from commercial paper (200) (150) — — Repayments of borrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — — (7) — Dividend payments (50) (49) (150) (149) Repurchases of stock and other (1) (4) (44) (532) Proceeds from issuances of stock 12 13 37 35 Net capital distributions to non-controlling interests (5) (2) (8) (5) Net cash used in financing activities (249) (217) (470) (730) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (3) 19 — 14 Net increase in cash, cash equivalents and restricted cash 491 505 256 96 Cash, cash equivalents and restricted cash at beginning of period 448 466 683 875 Cash, cash equivalents and restricted cash at end of period 939 971 939 971 Less: restricted cash at end of period 189 164 189 164	Cash flows from financing activities:					
Repayments of borrowings (5) (25) (2,041) (459) Payments for debt issuance costs — — — (7) — Dividend payments (50) (49) (150) (149) Repurchases of stock and other (1) (4) (44) (532) Proceeds from issuances of stock 12 13 37 35 Net capital distributions to non-controlling interests (5) (2) (8) (5) Net cash used in financing activities (249) (217) (470) (730) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (3) 19 — 14 Net increase in cash, cash equivalents and restricted cash 491 505 256 96 Cash, cash equivalents and restricted cash at beginning of period 448 466 683 875 Cash, cash equivalents and restricted cash at end of period 939 971 939 971 Less: restricted cash at end of period 189 164 189 164	Proceeds from debt issuance	_	_	1,743	380	
Payments for debt issuance costs — — — — — — — — — — — — — — — — — —	Net payments from commercial paper	(200)	(150)	_	_	
Dividend payments (50) (49) (150) (149) Repurchases of stock and other (1) (4) (44) (532) Proceeds from issuances of stock 12 13 37 35 Net capital distributions to non-controlling interests (5) (2) (8) (5) Net cash used in financing activities (249) (217) (470) (730) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Net increase in cash, cash equivalents and restricted cash 491 505 256 96 Cash, cash equivalents and restricted cash at beginning of period 448 466 683 875 Cash, cash equivalents and restricted cash at end of period 939 971 939 971 Less: restricted cash at end of period 189 164 189 164		(5)	(25)	(2,041)	(459)	
Repurchases of stock and other Proceeds from issuances of stock 12 13 37 35 Net capital distributions to non-controlling interests (5) (2) (8) (5) Net cash used in financing activities (249) (217) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period 448 466 483 875 Cash, cash equivalents and restricted cash at end of period 189 164 189		_	_		_	
Proceeds from issuances of stock Net capital distributions to non-controlling interests (5) Net cash used in financing activities (249) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Proceeds from issuances of stock (25) (217) (470) (730) 19 - 14 Net increase in cash, cash equivalents and restricted cash 491 505 256 96 Cash, cash equivalents and restricted cash at beginning of period 448 466 683 875 Cash, cash equivalents and restricted cash at end of period 939 971 164 189 164			(49)			
Net capital distributions to non-controlling interests (5) (2) (8) (5) Net cash used in financing activities (249) (217) (470) (730) Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (3) 19 - 14 Net increase in cash, cash equivalents and restricted cash 491 505 256 96 Cash, cash equivalents and restricted cash at beginning of period 448 466 683 875 Cash, cash equivalents and restricted cash at end of period 939 971 939 971 Less: restricted cash at end of period 189 164 189	·					
Net cash used in financing activities Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Less: restricted cash at end of period (249) (217) (470) (730) 490 14 14 1505 256 96 683 875 Cash, cash equivalents and restricted cash at end of period 939 971 939 971 164 189 164					35	
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period End of the company of the compa						
And restricted cash Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at end of period Page 19 Pag	-	(249)	(217)	(470)	(730)	
Cash, cash equivalents and restricted cash at beginning of period448466683875Cash, cash equivalents and restricted cash at end of period939971939971Less: restricted cash at end of period189164189164	Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	 (3)	19	_	14	
Cash, cash equivalents and restricted cash at end of period 939 971 939 971 Less: restricted cash at end of period 189 164 189 164	Net increase in cash, cash equivalents and restricted cash	491	505	256	96	
Less: restricted cash at end of period 189 164 189 164	Cash, cash equivalents and restricted cash at beginning of period	 448	466	683	875	
<u> </u>	Cash, cash equivalents and restricted cash at end of period	 939	971	939	971	
Cash and cash equivalents at end of period \$ 750 \$ 807 \$ 750 \$ 807	Less: restricted cash at end of period	189	164	189	164	
	Cash and cash equivalents at end of period	\$ 750	\$ 807	\$ 750	\$ 807	

LEIDOS HOLDINGS, INC. UNAUDITED SEGMENT OPERATING RESULTS (in millions)

		Three Mo	onths End	ded	Nine Months Ended					
	Se	ptember 29, 2023	Se	ptember 30, 2022	September 29, 2023		Se	eptember 30, 2022		
Revenues:										
Defense Solutions	\$	2,221	\$	2,075	\$	6,520	\$	6,176		
Civil		924		874		2,703		2,526		
Health		776		659		2,235		1,997		
Total	\$	3,921	\$	3,608	\$	11,458	\$	10,699		
Operating (loss) income:										
Defense Solutions	\$	147	\$	137	\$	469	\$	409		
Civil		(607)		79		(503)		160		
Health		152		91		381		335		
Corporate		(28)		(26)		(87)		(81)		
Total	\$	(336)	\$	281	\$	260	\$	823		
Operating (loss) income margin:										
Defense Solutions		6.6 %	.	6.6 %		7.2 %		6.6 %		
Civil		(65.7)%	,	9.0 %		(18.6)%		6.3 %		
Health		19.6 %	.	13.8 %		17.0 %		16.8 %		
Total		(8.6)%	.	7.8 %		2.3 %		7.7 %		

Defense Solutions

Defense Solutions revenues of \$2.22 billion increased by 7% compared to the prior year quarter. Revenue growth was primarily in the areas of digital modernization, including the Navy Next Generation Enterprise Network Recompete (NGEN-R) Service Management, Integration and Transport (SMIT) contract, and offensive and defensive hypersonics programs as well as the acquisition of Cobham Special Missions that was completed on October 30, 2022. For the quarter Defense Solutions operating income margin remained unchanged from 6.6% in the prior year quarter, and non-GAAP operating income margin increased to 8.4% from 8.1% in the prior year quarter. The increase in segment profitability was attributable to milestone achievements and cost control.

Civil

Civil revenues of \$924 million increased by 6% compared to the prior year quarter. The primary drivers of revenue growth were higher volumes within the security products portfolio, infrastructure spending by the Federal Aviation Administration (FAA), and increased demand for engineering support to commercial energy companies. Civil operating income margin for the quarter was (65.7)%, compared to 9.0% in the prior year quarter, primarily as a result of non-cash impairment and restructuring charges of \$688 million related to the SES reporting unit. Non-GAAP operating income margin was 10.4%, compared to 11.0% in the prior year quarter. The year-over-year segment profitability decreased as a result of the mix of security product sales.

Health

Health revenues of \$776 million increased by 18% compared to the prior year quarter driven by higher levels of medical examinations and growth on the Social Security Administration (SSA) Information Technology Support Services Contract II (ITSSC II). Health operating income margin for the quarter was 19.6%, compared to 13.8% in the prior year quarter, and non-GAAP operating margin was 20.4%, compared to 15.0% in the prior year quarter. The increase in segment profitability was driven primarily by increased volumes, higher incentive awards, and recovery of prior expenditures in the medical examination business.

LEIDOS HOLDINGS, INC. UNAUDITED BACKLOG BY REPORTABLE SEGMENT (in millions)

Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts. Backlog value is based on management's estimates about volume of services, availability of customer funding and other factors, and excludes contracts that are under protest. Estimated backlog comprises both funded and negotiated unfunded backlog. Backlog estimates are subject to change and may be affected by several factors, including modifications of contracts, non-exercise of options and foreign currency movements.

Funded backlog for contracts with the U.S. government represents the value on contracts for which funding is appropriated less revenues previously recognized on these contracts. Funded backlog for contracts with non-U.S. government entities and commercial customers represents the estimated value on contracts, which may cover multiple future years, under which Leidos is obligated to perform, less revenue previously recognized on the contracts.

Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from contracts for which funding has not been appropriated and unexercised priced contract options. Negotiated unfunded backlog does not include unexercised option periods and future potential task orders expected to be awarded under IDIQ, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded or separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.

The estimated value of backlog as of the dates presented was as follows:

	:	Sep	tember 29, 202	3		September 30, 2022							
Segment	 Funded		Unfunded		Total		Funded		Unfunded		Total		
Defense Solutions	\$ 4,994	\$	14,568	\$	19,562	\$	4,178	\$	13,842	\$	18,020		
Civil	2,297		9,602		11,899		2,037		8,652		10,689		
Health	1,756		4,826		6,582		1,214		5,105		6,319		
Total	\$ 9,047	\$	28,996	\$	38,043	\$	7,429	\$	27,599	\$	35,028		

Total backlog as of September 29, 2023, as compared to September 30, 2022, included \$610 million of backlog acquired through a business combination in the Defense Solutions reportable segment.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES

Leidos uses and refers to organic revenue, non-GAAP operating income, non-GAAP operating margin, adjusted EBITDA, adjusted EBITDA margin, non-GAAP diluted EPS, non-GAAP free cash flow and non-GAAP free cash flow conversion, which are not measures of financial performance under generally accepted accounting principles in the U.S. and, accordingly, these measures should not be considered in isolation or as a substitute for the comparable GAAP measures and should be read in conjunction with Leidos's consolidated financial statements prepared in accordance with GAAP.

Management believes that these non-GAAP measures provide another representation of the results of operations and financial condition, including its ability to comply with financial covenants. These non-GAAP measures are frequently used by financial analysts covering Leidos and its peers. The computation of non-GAAP measures may not be comparable to similarly titled measures reported by other companies, thus limiting their use for comparability.

Organic revenues capture the revenue that is inherent in the underlying business excluding the impact of acquisitions and divestitures made within the prior year; it is computed as current revenues excluding revenues from acquisitions within the last 12 months and divestitures within the current and year-ago periods.

Non-GAAP operating income is computed by excluding the following discrete items from operating income:

- Acquisition, integration and restructuring costs Represents acquisition, integration, lease termination, severance costs, retention costs and asset markdowns related to acquisitions and restructuring activities.
- Amortization of acquired intangible assets Represents the amortization of the fair value of the acquired intangible assets.
- Derivative loss Represents the fair value loss associated with the foreign currency forward contract to hedge the preliminary purchase price for the Cobham acquisition in Australian dollars.
- Goodwill impairment charges Represents impairments of goodwill due to changes in actual performance against performance projected when the goodwill was acquired.
- · Asset impairment charges Represents impairments of long-lived intangible assets.

Non-GAAP operating margin is computed by dividing non-GAAP operating income by revenues.

Adjusted EBITDA is computed by excluding the following items from income before income taxes: (i) discrete items as identified above; (ii) interest expense; (iii) interest income; (iv) depreciation expense; and (v) amortization of internally developed intangible assets.

Adjusted EBITDA margin is computed by dividing adjusted EBITDA by revenues.

Non-GAAP net income is computed by excluding the discrete items listed under non-GAAP operating income and their related tax impacts.

Non-GAAP diluted EPS is computed by dividing net income attributable to Leidos common stockholders, adjusted for the discrete items as identified above and the related tax impacts, by the diluted weighted average number of common shares outstanding.

Non-GAAP free cash flow is computed by deducting expenditures for property, equipment and software from net cash provided by operating activities.

Non-GAAP free cash flow conversion is computed by dividing non-GAAP free cash flow by non-GAAP net income attributable to Leidos common stockholders; operating cash flow conversion is computed by dividing net cash provided by operating activities by net income attributable to Leidos shareholders.

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except growth percentages)

The following table presents the reconciliation of revenues to organic revenues by reportable segment and total operations:

		Three Mo	onths	Ended	
		September 29, 2023	;	September 30, 2022	Percent Change
Defense Solutions					
Revenues, as reported	\$	2,221	\$	2,075	7 %
Acquisition revenues ⁽¹⁾		28		_	
Organic revenues	\$	2,193	\$	2,075	6 %
Civil					
Revenues, as reported	\$	924	\$	874	6 %
Health					
Revenues, as reported	\$	776	\$	659	18 %
Total Operations					
Revenues, as reported	\$	3,921	\$	3,608	9 %
Acquisition revenues ⁽¹⁾		28		_	
Organic revenues	<u> </u>	3,893	\$	3,608	8 %

⁽¹⁾ Current period acquisition revenues reflect revenues in the current as reported figures for 12 months from closing of each acquisition. For the three months ended September 29, 2023, Defense Solutions segment acquisition revenues include the acquisition of Cobham Special Missions that was completed on October 30, 2022.

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the three months ended September 29, 2023:

					Thr	ree Months Ende	d S	eptember 29, 202	3			
	-	As reported		Acquisition, ntegration and restructuring costs ⁽³⁾	,	Amortization of acquired intangibles	Α	sset impairment charges		Goodwill impairment charges		Non-GAAP results
Operating (loss) income	\$	(336)	\$	17	\$	50	\$	88	\$	599	\$	418
Non-operating expense, net		(52)		_		_						(52)
(Loss) income before income taxes		(388)		17		50		88		599		366
Income tax expense ⁽¹⁾		(8)		(1)		9		(11)		(72)		(83)
Net (loss) income		(396)		16		59		77		527		283
Less: net income attributable to non- controlling interest		3		_		_		_		_		3
Net (loss) income attributable to Leidos common stockholders	\$	(399)	\$	16	\$	59	\$	77	\$	527	\$	280
Diluted EPS attributable to Leidos common stockholders ⁽²⁾	\$	(2.91)	\$	0.12	\$	0.43	\$	0.56	\$	3.82	\$	2.03
Diluted shares		137		138		138		138		138		138
					Thr	ee Months Ende	d Se	eptember 29, 2023	3			
	Α	As reported		Acquisition, ntegration and restructuring costs ⁽³⁾	Δ	Amortization of acquired intangibles	As	sset impairment charges		Goodwill impairment charges	Noi	n-GAAP results
Net (loss) income	\$	(396)	\$	16	\$	59	\$	77	\$	527	\$	283
Income tax expense ⁽¹⁾		8		1		(9)		11		72		83

\$

(Loss) income before income taxes

Depreciation expense

Interest expense, net

EBITDA margin

EBITDA

Amortization of intangibles

17

17

50

(50)

599

599

366 32

53

451

11.5 %

88

88

(388)

32

50

53

(253)

(6.5)%

⁽¹⁾ Calculation uses an estimated statutory tax rate on non-GAAP adjustments.

⁽²⁾ Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

⁽³⁾ Asset markdowns associated with restructuring activities were recorded to "Cost of revenues" in the condensed consolidated statements of operations.

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the three months ended September 30, 2022:

			Three Mor	nths Ended Septembe	r 30	, 2022		
	As reported	Acquis integration restructuri	on and	Amortization of acquired intangibles	Derivative loss		Non-GAAP results	
Operating income	\$ 281	\$	4	\$ 57	\$	_	\$	342
Non-operating expense, net	(60)		_	_		16		(44)
Income before income taxes	221		4	57		16		298
Income tax expense ⁽¹⁾	(57)		(1)	(15)		(4)		(77)
Net income	164		3	42		12		221
Less: net income attributable to non-controlling interest	2		_	_		_		2
Net income attributable to Leidos common stockholders	\$ 162	\$	3	\$ 42	\$	12	\$	219
Diluted EPS attributable to Leidos common stockholders ⁽²⁾	\$ 1.17	\$	0.02	\$ 0.31	\$	0.09	\$	1.59
Diluted shares	138		138	138		138		138

			-	Three Moi	nths I	Ended Septembe	r 30, 2022		
	As	reported	Acquis integrati restructuri	on and	Δ	Amortization of acquired intangibles	Derivative loss	Non	-GAAP results
Net income	 \$	164	\$	3	\$	42	\$ 12	\$	221
Income tax expense ⁽¹⁾		57		1		15	4		77
Income before income taxes		221		4		57	16		298
Depreciation expense		24		_		_	_		24
Amortization of intangibles		57		_		(57)	_		_
Interest expense, net		50		_		_	_		50
EBITDA	\$	352	\$	4	\$	_	\$ 16	\$	372
EBITDA margin	_	9.8 %							10.3 %

⁽¹⁾ Calculation uses an estimated statutory tax rate on non-GAAP adjustments.

⁽²⁾ Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the nine months ended September 29, 2023:

				Nir	ne Months Ended	Septen	nber 29, 2023			
	-	As reported	Acquisition, ntegration and restructuring costs ⁽³⁾	ļ	Amortization of acquired intangibles		impairment harges	Goodwill impairment charges	No	n-GAAP results
Operating income	\$	260	\$ 26	\$	153	\$	88	\$ 599	\$	1,126
Non-operating expense, net		(167)	_		_		_			(167)
Income before income taxes		93	26		153		88	599		959
Income tax expense ⁽¹⁾		(115)	(3)		(18)		(11)	(72)		(219)
Net (loss) income		(22)	23		135		77	527		740
Less: net income attributable to non-controlling interest		8	_		_		_	_		8
Net (loss) income attributable to Leidos common stockholders	\$	(30)	\$ 23	\$	135	\$	77	\$ 527	\$	732
							_			
Diluted EPS attributable to Leidos common stockholders ⁽²⁾	\$	(0.22)	\$ 0.17	\$	0.98	\$	0.56	\$ 3.82	\$	5.30
Diluted shares		137	138		138		138	138		138

					Nin	e Months Ended	d Se	ptember 29, 202	3			
		As reported	int	Acquisition, egration and estructuring costs ⁽³⁾	Α	Amortization of acquired intangibles	As	sset impairment charges		Goodwill impairment charges	Nor	n-GAAP results
Net (loss) income	\$	(22)	\$	23	\$	135	\$	77	\$	527	\$	740
Income tax expense ⁽¹⁾		115		3		18		11		72		219
Income before income taxes	,	93		26		153		88		599		959
Depreciation expense		95		_		_		_		_		95
Amortization of intangibles		153		_		(153)		_		_		_
Interest expense, net		163		_		_		_		_		163
EBITDA	\$	504	\$	26	\$	_	\$	88	\$	599	\$	1,217
EBITDA margin	·	4.4 %								,		10.6 %

⁽¹⁾ Calculation uses an estimated statutory tax rate on non-GAAP adjustments.

⁽²⁾ Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

⁽³⁾ Asset markdowns associated with restructuring activities were recorded to "Cost of revenues" in the condensed consolidated statements of operations.

The following tables present the reconciliation of non-GAAP operating income, net income, diluted EPS, adjusted EBITDA, and adjusted EBITDA margin to the most directly comparable GAAP measures for the nine months ended September 30, 2022:

				Nii	ne Months Ended	September 30, 2022	-			
	As rep	orted	Acquisition, integration and restructuring costs	,	Amortization of acquired intangibles	Asset impairment charges		Derivative loss	No	on-GAAP results
Operating income	\$	823	\$ 12	\$	172	\$ 3	\$		\$	1,010
Non-operating expense, net		(155)	_		_	_		16		(139)
Income before income taxes		668	12		172	3		16		871
Income tax expense ⁽¹⁾		(155)	(3)		(44)	(1)	(4)		(207)
Net income		513	9		128			12		664
Less: net income attributable to non-controlling interest		5	_		_	_		_		5
Net income attributable to Leidos common stockholders	\$	508	\$ 9	\$	128	\$ 2	\$	12	\$	659
Diluted EPS attributable to Leidos common stockholders (2)	\$	3.68	\$ 0.07	\$	0.93	\$ 0.01	\$	0.09	\$	4.78
Diluted shares		138	138		138	138		138		138

				Nir	ne Months Ended	Sep	otember 30, 2022				
	As reported	int	Acquisition, tegration and ructuring costs	A	Amortization of acquired intangibles	A	sset impairment charges	D	erivative loss	N	on-GAAP results
Net income	\$ 513	\$	9	\$	128	\$	2	\$	12	\$	664
Income tax expense ⁽¹⁾	155		3		44		1		4		207
Income before income taxes	 668		12		172		3		16		871
Depreciation expense	76		_		_		_		_		76
Amortization of intangibles	173		_		(172)		_		_		1
Interest expense, net	148		_		_		_		_		148
EBITDA	\$ 1,065	\$	12	\$		\$	3	\$	16	\$	1,096
EBITDA margin	 10.0 %										10.2 %

⁽¹⁾ Calculation uses an estimated statutory tax rate on non-GAAP adjustments.
(2) Earnings per share is computed independently for each of the non-GAAP adjustment presented and therefore may not sum to the total non-GAAP earnings per share due to rounding.

The following tables present the reconciliation of non-GAAP operating income by reportable segment and Corporate to operating income:

				Three Mon	ths	Ended Septen	nbe	er 29, 2023		
	perating ome (loss)	int	Acquisition, tegration and estructuring costs ⁽¹⁾	mortization of acquired intangibles		Goodwill impairment charges		Asset impairment charges	Non-GAAP operating scome (loss)	Non-GAAP operating margin
Defense Solutions	\$ 147	\$	3	\$ 29	\$	_	\$	8	\$ 187	8.4 %
Civil	(607)		9	15		599		80	96	10.4 %
Health	152		_	6		_		_	158	20.4 %
Corporate	(28)		5	_		_		_	(23)	NM
Total	\$ (336)	\$	17	\$ 50	\$	599	\$	88	\$ 418	10.7 %

			Three Moi	nths E	nded Septem	ber 30,	, 2022	
	rating e (loss)	inte	equisition, egration and structuring costs		ortization of acquired ntangibles	op	n-GAAP perating ome (loss)	Non-GAAP operating margin
Defense Solutions	\$ 137	\$	_	\$	32	\$	169	8.1 %
Civil	79		_		17		96	11.0 %
Health	91		_		8		99	15.0 %
Corporate	(26)		4		_		(22)	NM
Total	\$ 281	\$	4	\$	57	\$	342	9.5 %

				Nine Mont	hs E	Ended Septem	be	r 29, 2023		
	rating ne (loss)	int	Acquisition, egration and estructuring costs ⁽¹⁾	mortization of acquired intangibles	i	Goodwill mpairment charges		Asset impairment charges	Non-GAAP operating come (loss)	Non-GAAP operating margin
Defense Solutions	\$ 469	\$	3	\$ 88	\$	_	\$	8	\$ 568	8.7 %
Civil	(503)		10	48		599		80	234	8.7 %
Health	381		_	17		_		_	398	17.8 %
Corporate	(87)		13	_		_		_	(74)	NM
Total	\$ 260	\$	26	\$ 153	\$	599	\$	88	\$ 1,126	9.8 %

	Nine Months Ended September 30, 2022												
	Opera income		inte	equisition, gration and structuring costs		nortization of acquired ntangibles		Asset impairment charges		Non-GAAP operating ncome (loss)	Non-GAAP operating margin		
Defense Solutions	\$	409	\$		\$	97	\$		\$	506	8.2 %		
Civil		160		_		53		_		213	8.4 %		
Health		335		_		22		3		360	18.0 %		
Corporate		(81)		12		_		_		(69)	NM		
Total	\$	823	\$	12	\$	172	\$	3	\$	1,010	9.4 %		

⁽¹⁾ Asset markdowns associated with restructuring activities were recorded to "Cost of revenues" in the condensed consolidated statements of operations. NM - Not Meaningful

LEIDOS HOLDINGS, INC. UNAUDITED NON-GAAP FINANCIAL MEASURES [CONTINUED] (in millions, except percentages)

The following table presents the reconciliation of non-GAAP free cash flow to net cash provided by operating activities as well as the calculation of operating cash flow and non-GAAP free cash flow conversion ratios:

	Three Months Ended								
	Septer	nber 29, 2023	Septe	mber 30, 2022					
Net cash provided by operating activities ⁽¹⁾	\$	795	\$	729					
Payments for property, equipment and software		(50)		(27)					
Non-GAAP free cash flow	\$	745	\$	702					
				_					
Net (loss) income attributable to Leidos common stockholders	\$	(399)	\$	162					
Acquisition, integration and restructuring costs ⁽²⁾⁽³⁾		16		3					
Amortization of acquired intangibles ⁽²⁾		59		42					
Goodwill impairment charges ⁽²⁾		527		_					
Asset impairment charges ⁽²⁾		77		_					
Derivative loss ⁽²⁾		_		12					
Non-GAAP net income attributable to Leidos common stockholders	\$	280	\$	219					
Operating cash flow conversion ratio		(199)%)	450 %					
Non-GAAP free cash flow conversion ratio		266 %)	321 %					

⁽¹⁾ Prior year financial information has been reclassified to reflect the effect of foreign exchange rate changes on cash, cash equivalents and restricted cash in net cash provided by operating activities.

⁽²⁾ After-tax expenses excluded from non-GAAP net income.

⁽³⁾ Asset markdowns associated with restructuring activities were recorded to "Cost of revenues" in the condensed consolidated statements of operations.